IBRX (ImmunityBio) Total Liabilities: $1,674.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBRX ImmunityBio Inc IBRX
60 GF Score
Price $8.40
GF Value $22.43
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ImmunityBio Total Liabilities?

ImmunityBio IBRX +1.82% 60 Total Liabilities is $1,674.3 Mil as of Jun. 2026. GuruFocus rates IBRX with a GF Score™ of 60/100 and a GF Value™ of $22.43 (Possible Value Trap). The stock has 5 warning signs investors should review.

ImmunityBio's Total Liabilities for the quarter that ended in Jun. 2026 was $1,674.3 Mil.

ImmunityBio's quarterly Total Liabilities increased from Dec. 2025 ($1,001.47 Mil) to Mar. 2026 ($1,515.76 Mil) and increased from Mar. 2026 ($1,515.76 Mil) to Jun. 2026 ($1,674.27 Mil).

ImmunityBio's annual Total Liabilities declined from Dec. 2023 ($1,090.39 Mil) to Dec. 2024 ($871.06 Mil) but then increased from Dec. 2024 ($871.06 Mil) to Dec. 2025 ($1,001.47 Mil).

ImmunityBio Total Liabilities Historical Data

* Premium members only.

The historical data trend for ImmunityBio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio Total Liabilities Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 712.82 812.18 1,090.39 871.06 1,001.47

ImmunityBio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 971.90 1,042.40 1,001.47 1,515.76 1,674.27
IBRX
60GF Score
ImmunityBio Inc IBRX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmunityBio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ImmunityBio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=61.754+(510.54+429.178
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,001.5

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=501.898--499.574
=1,001.5

ImmunityBio's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=76.727+(805.553+791.985
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1,674.3

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=628.504--1045.761
=1,674.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1,674.3 Mil mean?
ImmunityBio (IBRX) has a Total Liabilities of $1,674.3 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ImmunityBio and its competitors.
Is ImmunityBio's Total Liabilities too high?
ImmunityBio's current Total Liabilities is $1,674.3 Mil. Overall, ImmunityBio has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImmunityBio's Total Liabilities compare to RYTM and PCVX?
ImmunityBio's Total Liabilities of $1,674.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ImmunityBio and its competitors. ImmunityBio's current Total Liabilities is $1,674.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmunityBio stock overvalued right now?
Based on GuruFocus' analysis, ImmunityBio (IBRX) is currently considered Possible Value Trap. The stock's GF Value™ is $22.43, compared to a current price of $8.40 — trading 62.6% below its estimated fair value. The current Total Liabilities is $1,674.3 Mil. ImmunityBio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ImmunityBio (IBRX), the current Total Liabilities is $1,674.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmunityBio (IBRX) Overvalued in 2026?

Based on GuruFocus' analysis, ImmunityBio stock appears to be undervalued. The current stock price of $8.40 is trading 62.6% below its estimated GF Value™ of $22.43. GuruFocus considers ImmunityBio to be Possible Value Trap.

Key valuation signals for IBRX:

  • Total Liabilities: $1,674.3 Mil
  • GF Value™: $22.43 vs. price of $8.40 (62.6% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the IBRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmunityBio Business Description

Other Exchanges 26CA:Germany
Address 3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
60GF Score

Get the complete analysis for IBRX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price
$22.43
GF Value